Stem Cell Clinic

Test predicts response to treatment for complication of leukemia stem cell treatment

By Stem Cell Treatment

(New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.

Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a life-threatening complication and major cause of death after SCT. The disease, which can be mild to severe, occurs when the transplanted donor cells (known as the graft) attack the patient (referred to as the host). Symptom severity, however, does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids. Although SCT cures cancer in 50 percent of the patients, 25 percent die from relapsed cancer and there remaining go into remission but later succumb to effects of GVHD.

"High dose steroids is the only proven treatment for GVHD," said James L. M. Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine Professor at the Icahn School of Medicine at Mount Sinai, Director of Hematologic Malignancies Translational Research Center at Tisch Cancer Institute at Mount Sinai. "Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk."

Dr. Ferrara, along with a multi-center team of researchers, developed and tested this new scoring system using almost 500 patient blood samples with newly diagnosed GVHD in varying grades from two different centers. They used three validated biomarkers TNFR1, ST2 and Reg3 to create an algorithm that calculated the probability of non-relapse mortality (usually caused by GVHD) that provided three distinct risk scores to predict the patient's response to GVHD treatment.

The acid test was to evaluate the algorithm in a validation set of 300 additional patients from twenty different SCT centers throughout the US. The algorithm worked perfectly, and the cumulative incidence of non-relapse mortality significantly increased as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.

"This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach," said Dr. Ferrara. "And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients."

In order to capitalize on this discovery, Dr. Ferrara has created the Mount Sinai Acute GVHD International Consortium (MAGIC) which consists of a group of ten SCT centers in the US and Europe who will collaborate to use this new scoring system to test new treatments for acute GVHD. Dr. Ferrara and colleagues have also written a protocol to treat high-risk GVHD that has been approved by the FDA.

###

Co-collaborators included University of Michigan, University of Regensburg, and the Blood and Marrow Clinical Trials Network.

The study was supported by grants from the National Cancer Institute; the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the Doris Duke Charitable Fund, the American Cancer Society, and the Judith Devries Fund.

Read the rest here:
Test predicts response to treatment for complication of leukemia stem cell treatment

Test Predicts Response to Early Treatment for Dangerous Complication of Stem Cells Transplants Used in Leukemia Patients

By Stem Cell Treatment

Contact Information

Available for logged-in reporters only

Newswise (New York City) A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life-threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.

Patients with fatal blood cancers like leukemia often require allogenic stem cell SCT to survive. Donor stem cells are transplanted to a recipient, but not without the risk of developing GVHD, a life-threatening complication and major cause of death after SCT. The disease, which can be mild to severe, occurs when the transplanted donor cells (known as the graft) attack the patient (referred to as the host). Symptom severity, however, does not accurately define how patients will respond to treatment and patients are often treated alike with high-dose steroids. Although SCT cures cancer in 50 percent of the patients, 25 percent die from relapsed cancer and there remaining go into remission but later succumb to effects of GVHD.

High dose steroids is the only proven treatment for GVHD, said James L. M. Ferrara, MD, DSc, Ward-Coleman Chair in Cancer Medicine Professor at the Icahn School of Medicine at Mount Sinai, Director of Hematologic Malignancies Translational Research Center at Tisch Cancer Institute at Mount Sinai. Those with low-risk GVHD are often over-treated and face significant side-effects from treatment. Patients with high risk GVHD are undertreated and the GVHD progresses, often with fatal consequences. Our goal is to provide the right treatment for each patient. We hope to identify those patients at higher risk and design an aggressive intervention while tailoring a less-aggressive approach for those with low-risk.

Dr. Ferrara, along with a multi-center team of researchers, developed and tested this new scoring system using almost 500 patient blood samples with newly diagnosed GVHD in varying grades from two different centers. They used three validated biomarkers TNFR1, ST2 and Reg3 to create an algorithm that calculated the probability of non-relapse mortality (usually caused by GVHD) that provided three distinct risk scores to predict the patients response to GVHD treatment.

The acid test was to evaluate the algorithm in a validation set of 300 additional patients from twenty different SCT centers throughout the US. The algorithm worked perfectly, and the cumulative incidence of non-relapse mortality significantly increased as the GVHD score increased, and so the response rate to primary GVHD treatment decreased.

This new scoring system will help identify patient who may not respond to standard treatments, and may require an experimental and more aggressive approach, said Dr. Ferrara. And it will also help guide treatment for patients with lower-risk GVHD who may be over-treated. This will allow us to personalize treatment at the onset of the disease. Future algorithms will prove increasingly useful to develop precision medicine for all SCT patients.

In order to capitalize on this discovery, Dr. Ferrara has created the Mount Sinai Acute GVHD International Consortium (MAGIC) which consists of a group of ten SCT centers in the US and Europe who will collaborate to use this new scoring system to test new treatments for acute GVHD. Dr. Ferrara and colleagues have also written a protocol to treat high-risk GVHD that has been approved by the FDA.

Co-collaborators included University of Michigan, University of Regensburg, and the Blood and Marrow Clinical Trials Network.

Follow this link:
Test Predicts Response to Early Treatment for Dangerous Complication of Stem Cells Transplants Used in Leukemia Patients

Doctors think stem cell injections could provide hope for Huntington disease patients

By Stem Cell Doctors

SOUTH BEND, Ind.--- Mike and Katie have been a couple since college, but they've known each other much longer.

"We've been together forever," said Mike.

"I've actually known Mike since I was 5-years-old," said Katie.

A marriage and three kids later they've been through good times, and bad. The worst came nine-years-ago when Mike found out he had Huntington's disease.

Huntington's is a deadly, inherited disease that affects about 30,000 Americans; 150,000 more are at risk.

Until now there has been no hope for these patients, who typically die of the disease within 15 years of diagnosis.

"My father had it, said Mike. He died from it."

Huntington's causes uncontrollable movements and mental decline, there is no cure.

"Unfortunately, it ends in death, said Dr. Vicki Wheelock, a neurologist at UC Davis Health System. It's a fatal disease."

Now researchers are gearing up for a new trial in humans.

Visit link:
Doctors think stem cell injections could provide hope for Huntington disease patients

Pearland boy makes remarkable recovery via stem cells

By Stem Cell Doctors

Six-year-old Pearland resident Tucker Beau Hyatt has known that he has been battling Monstritis for a long time. He has taken on the guise of Batman (shhh!) in order to beat it.

Monstritis was the then two-year-old Tuckers way of understanding his diagnosis of Systemic Juvenile Idiopathic Arthritis (JIA), a rare form of Rheumatoid Arthritis that affects about 300,000 children in the U.S. Over time, the membranes in the joints wear down, causing severe pain, loss of appetite and mobility.

Tuckers mother, Linsey Hyatt, recalls that it all started with a very high fever and a rash all over Tuckers body. We took him to the pediatrician thinking it was just some sort of infection, she said.

The blood work came back all over the place, and the youngster was referred to an Infectious Disease Specialist at Texas Tech.

The doctor took one look at Tucker and his chart and instantly knew what it was, Hyatt said.

By that time, Tucker had stopped eating and was unable to walk. We went to a rheumatoid specialist in Austin, which was the closest doctor to Midland, where we were living at the time, recalls Hyatt. They started him on chemotherapy, which was awful.

Tuckers mom and dad, Todd Hyatt, never stopped searching for a better solution to help their son, who was slowly wasting away from the disease. This is not a quick thing, said Linsey. Its slow and painful.

The Hyatts moved to Pearland in June of 2013 because of Todds job. They had become active with the Arthritis Foundation right after Tuckers diagnosis and attended an RAF luncheon in Austin featuring former Houston Oiler Earl Campbell, who suffers from osteoarthritis, in February 2014.

It was there that they first heard about Celltex, a company that facilitates stem cell therapy for RA, Multiple Sclerosis, Parkinsons and other autoimmune diseases.

We wanted to be able to tell Tucker Beau that we had done everything possible to help him, said Linsey.

Originally posted here:
Pearland boy makes remarkable recovery via stem cells

Stem Cell Scandal Scientist Haruko Obokata Resigns

By Stem Cell Medicine

A Japanese Stem Cell Scientist At The Heart Of A Scandal Over False Claims And Fabricated Research Has Resigned.

Dr Haruko Obokata published supposedly groundbreaking research showing stem cells could be made quickly and cheaply.

There were irregularities in data, no other group in the world could repeat her findings and her own university concluded it could not be done.

In a statement Dr Obokata said: "I even can't find the words for an apology."

Stem cells can become any other type of tissue and hold great potential in medicine.

They are already being investigated to heal the damage caused by a heart attack and to restore sight.

But they are expensive and difficult to produce and one source - embryos - raises serious ethical questions.

'Major discovery'

Dr Obokata's scientific paper published in the prestigious journal Nature claimed that stem cells could be produced from normal adult cells by dipping them into acid for a 30-minute shock period.

The announcement of the creation of these "Stap" cells (stimulus-triggered acquisition of pluripotency) sent shockwaves around the world.

Read more:
Stem Cell Scandal Scientist Haruko Obokata Resigns

Official lured big-dollar donor into giving $100 million for flashy stem cell center.

By Stem Cell Medical Center

A high-dollar fundraiser for the so-called health sciences branch of UCSD is heading off to the City of Hope in Duarte to become chief rainmaker there.

Kristin Jean Bertell, who was named associate vice chancellor for Health Sciences Development at UCSD two years ago in October, received gross pay of $247,800 in 2013, according to the University of California's salary website.

Set to report in February as "chief philanthropy officer, Bartell will "provide executive and strategic oversight for all aspects of City of Hopes philanthropic efforts, as the cancer treatment center and biomedical research institution enters a new era of growth and development," according to the nonprofit's announcement of the move.

A year before being named associate vice chancellor, Bertell became "executive director of development for principal gifts" for UCSD's health sciences operation.

Prior to that the UCLA graduate had variously served as vice president for Institute Relations at the Salk Institute for Biological Studies, and as a senior vice president of the Greenwood Company in San Francisco, which "is particularly well-known for the development of successful fundraising strategies for health care institutions grappling with the fundraising challenges caused by health systems, tightening institutional budgets, [and] dramatic changes in the delivery of health care and managed care," the firm's website says.

Luring elderly high-rollers into funding flashy medical centers named after themselves has grown into a multibillion-dollar national business, and Bertell is no slacker, credited in the City of Hope's December 15 news release with having been "the primary development lead in securing a landmark $100 million donation" for UCSD's Sanford Stem Cell Clinical Center.

The cash came from billionaire T. Denny Sanford, who piled up big money at South Dakota's First Premier bank issuing high-interest credit cards to so-called credit-impaired customers.

"First Premier now has 3 million active cardholders," Forbes reported in 2007. "Its cards are to be avoided if possible they have 10% to 20% interest rates but cost $175 in fees to get a card with a $1,000 limit. The typical customer stays only 18 months before graduating to something better. 'We provide a lifeline for credit-impaired people,' Sanford says."

According to UCSD's website, "His gift to create the Sanford Stem Cell Clinical Center is the second largest donation received by UC San Diego in its 53-year history, following only the $110 million gift by Joan and Irwin Jacobs to endow the UC San Diego Jacobs School of Engineering."

Go here to see the original:
Official lured big-dollar donor into giving $100 million for flashy stem cell center.

Knee meniscus fixed using revolutionary stem cell procedure

By Stem Cell Medical Center

Meg Goodale

Lise Fortier checks the meniscus of a sheep that she operated on last summer, using a groundbreaking new procedure to regenerate knee meniscus.

Researchers report on a revolutionary new procedure that uses 3-D printing and the bodys stem cells to regenerate knee meniscus, a tissue lining that acts as a natural cushion between the femur and tibia.

People with damaged menisci develop arthritis and are forced to limit their activity.

The procedure, published online Dec. 10 in the journal Science Translational Medicine, has proved successful in sheep at Cornell University six months after surgery, though the researchers will monitor the sheep for a year to ensure the animals do not develop arthritis. Sheep menisci are structurally similar to those of humans, and clinical trials in humans could begin in two to three years.

Most middle-aged people who end up with a degenerate meniscus have it trimmed up [surgically], but if you lose more than 20 to 30 percent, then you are very prone to arthritis, said Lisa Fortier, professor of large animal surgery at Cornells College of Veterinary Medicine and a co-author of the paper; she led the meniscus surgeries on sheep. If everybody who needed it could replace their meniscus they could slow arthritis and maintain their full function, Fortier added.

The technique was developed by the papers senior author Jeremy Mao, professor of dental medicine at Columbia University Medical Center, and involves taking an MRI of the patients (in this case sheeps) knee. Using a 3-D printer, Mao printed a biodegradable polyester scaffold in the exact shape of a patients meniscus. Through multiple lab experiments, Maos group discovered that two growth factors, when used in specific concentrations and at critical times, recruited the most stem cells for meniscal repair. The growth factors were then laced into the scaffold, allowing the bodys stem cells build a new meniscus four to six weeks after surgery.

Currently, a torn meniscus requires replacement with cadaver tissue, which has a low success rate and can lead to disease and rejection, and synthetic menisci have proved ineffective and hard to fit properly in diversely built patients.

Approximately a million people undergo meniscus surgeries each year in the United States.

Co-authors include Scott Rodeo, orthopedic surgeon at the Hospital for Special Surgery, an affiliate of Weill Cornell Medical College; and Chang H. Lee, Chuanyong Lu and Cevat Erisken, all at Columbia University Medical Center.

Read more from the original source:
Knee meniscus fixed using revolutionary stem cell procedure

Stem Cell Therapy in Pune | Stem Cell Treatment | Inamdar …

By Uncategorized

The potential of SCs to replace dead or damaged cells in any tissue of the body heralds the advent of a new field of medicine that is delivering cures for diseases now thought to be untreatable

Stem cell therapy represents a promising avenue for the treatment of disorders like

Q1: What are stem cells? Answer: Stem cells are class of undifferentiated cells that are able to differentiate into specialized cell types .They have the unique properties of self renewal and differentiation. Differentiation property of stem cells help them to form another type of cell with more specialized function such as brain cell, red blood cell or muscle cell and also the entire organ. During the foetal development, cells divide, migrate, specialize and form the organ. After birth, stem cells are also present in bone marrow which can be used to treat various diseases.

Q2: Which disorders can be treated using Stem Cells? Answer: Currently stem cells are being used successfully to treat various (disorders) diseases like Cerebral palsy, Spinal Cord Injury, Traumatic brain injury, Paralysis, Brain Stroke Osteoarthritis, Autism etc. Apart from this, stem cells can be used to treat liver disorders and Diabetes.

Q3: How is Stem Cell Therapy carried out? Answer: Stem Cell therapy is a very simple and painless process.Mesenchymal stem cells are injected directly into the synivial fluid in the knee. The whole process is carried out very carefully under sterile conditions.

Continued here:
Stem Cell Therapy in Pune | Stem Cell Treatment | Inamdar ...

Family: Experimental stem-cell treatment does wonders for Gordie Howe

By Stem Cell Treatment

Updated DEC 19, 2014 6:19p ET

Call it a Christmas miracle. That's pretty much the way Gordie Howe's family is describing his extraordinary recovery -- thanks to an experimental stem-cell treatment -- from a series of strokes that appeared to threaten the 86-year-old hockey legend's life only a few weeks ago.

"This is truly a Christmas miracle," said Dr. Murray Howe, a Toledo physician and one of Gordie's four children. "I would not have believed it if I hadn't seen it with my own eyes. "

Howe, gravely ill at the time, underwent the treatment on Dec. 8 in San Diego.

"As a family, we are thrilled that Dad's quality of life has greatly improved, and his progress has exceeded our greatest expectations," the Howe family said Friday in a news release in which it thanked a legion of fans praying for its father's recovery. "Once again, we cannot emphasize how much you have fueled Mr. Hockey's recovery, and we thank everyone for their continued prayers and support."

The neural stem cells were injected into the spinal canal on Day 1 and mesenchymal stem cells by intravenous infusion on Day 2, according to the release.

"His response was truly miraculous," the family said. "At the end of Day 1, he was walking with minimal effort for the first time since his stroke. By Day 2, he was conversing comfortably with family and staff at the clinic. On the third day, he walked to his seat on the plane under his own power."

Just five days later, Howe was walking unaided and even taking part in daily household chores, according to the release.

When tested, his ability to name items has gone from less than 25 percent before the procedure to 85 percent today, the release said.

"His physical therapists have been astonished," the family said. "Although his short-term memory, strength, endurance and coordination have plenty of room for improvement, we are hopeful that he will continue to improve in the months to come."

Read more:
Family: Experimental stem-cell treatment does wonders for Gordie Howe

→←